Abstract
Braille labels and instructions on medicine packaging are scarce in China, impeding blind individuals’ ability to obtain information about medications. Article 37 of China’s Barrier-Free Environment Creation Law, enacted in September 2023, requires braille labelling and instructions for pharmaceuticals. This provision offers essential legal protection to ensure the safety of blind individuals when using medications. Nevertheless, the use of braille labels and instructions for medicines is hindered by ambiguous statutes, limited social consciousness, financial factors and technological constraints. To promote the use of braille on medicinal labels and instructions, China should bolster its legislation, increase social consciousness, alleviate the financial strain on pharmaceutical manufacturers, foster technological advancement and encourage collaboration and self-governance within the pharmaceutical industry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
